IMAC (BACK) Competitors $0.07 0.00 (-0.14%) As of 01:53 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock BACK vs. BTTX, UPHL, OPGN, ACONW, AONC, DHACW, LFMDP, OTRKP, PIIIW, and TALKWShould you be buying IMAC stock or one of its competitors? The main competitors of IMAC include Better Therapeutics (BTTX), UpHealth (UPHL), OpGen (OPGN), Aclarion (ACONW), American Oncology Network (AONC), Digital Health Acquisition (DHACW), LifeMD (LFMDP), Ontrak (OTRKP), P3 Health Partners (PIIIW), and Talkspace (TALKW). These companies are all part of the "healthcare" industry. IMAC vs. Its Competitors Better Therapeutics UpHealth OpGen Aclarion American Oncology Network Digital Health Acquisition LifeMD Ontrak P3 Health Partners Talkspace Better Therapeutics (NASDAQ:BTTX) and IMAC (NASDAQ:BACK) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability. Which has preferable valuation & earnings, BTTX or BACK? IMAC has higher revenue and earnings than Better Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBetter TherapeuticsN/AN/A-$39.76MN/AN/AIMAC$72.05K2.04-$9.42MN/AN/A Which has more volatility and risk, BTTX or BACK? Better Therapeutics has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500. Comparatively, IMAC has a beta of 2.19, indicating that its share price is 119% more volatile than the S&P 500. Does the media favor BTTX or BACK? In the previous week, Better Therapeutics' average media sentiment score of 0.00 equaled IMAC'saverage media sentiment score. Company Overall Sentiment Better Therapeutics Neutral IMAC Neutral Do insiders & institutionals believe in BTTX or BACK? 34.0% of Better Therapeutics shares are owned by institutional investors. Comparatively, 5.8% of IMAC shares are owned by institutional investors. 51.4% of Better Therapeutics shares are owned by insiders. Comparatively, 12.3% of IMAC shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is BTTX or BACK more profitable? Company Net Margins Return on Equity Return on Assets Better TherapeuticsN/A N/A N/A IMAC N/A N/A -325.44% SummaryBetter Therapeutics and IMAC tied by winning 3 of the 6 factors compared between the two stocks. Get IMAC News Delivered to You Automatically Sign up to receive the latest news and ratings for BACK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BACK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BACK vs. The Competition Export to ExcelMetricIMACSpecialty outpatient clinics IndustryMedical SectorNASDAQ ExchangeMarket Cap$147K$147K$5.68B$9.81BDividend YieldN/AN/A4.61%4.07%P/E RatioN/AN/A30.6825.56Price / Sales2.042.04464.10116.64Price / CashN/AN/A38.2159.48Price / Book-0.11N/A8.996.13Net Income-$9.42M-$9.42M$3.25B$264.89M7 Day PerformanceN/AN/A4.78%2.67%1 Month PerformanceN/AN/A6.80%3.11%1 Year PerformanceN/AN/A30.61%25.14% IMAC Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BACKIMACN/A$0.07-0.1%N/A-96.0%$147K$72.05K0.00180BTTXBetter TherapeuticsN/A$0.00flatN/AN/A$5KN/A0.0040UPHLUpHealth0.3474 of 5 stars$0.00flatN/A-99.9%$4K$130M0.001,750News CoverageOPGNOpGenN/A$0.00-99.7%N/AN/A$1K$2.67M0.00100News CoverageGap DownACONWAclarionN/A$0.04+35.8%N/AN/A$0.00$54.60K0.007AONCAmerican Oncology NetworkN/A$12.24+2.0%N/A+257.5%$0.00$1.34B0.001,520High Trading VolumeDHACWDigital Health AcquisitionN/A$0.05-9.0%N/A-76.8%$0.00N/A0.00N/AGap UpLFMDPLifeMDN/A$23.83+1.6%N/A+9.6%$0.00$245.56M0.00230Short Interest ↓OTRKPOntrakN/A$0.02-6.3%N/A-94.2%$0.00$10.84M0.00250High Trading VolumePIIIWP3 Health PartnersN/A$0.01flatN/AN/A$0.00$1.49B0.00500News CoverageGap UpTALKWTalkspaceN/A$0.07+1.4%N/A+31.8%$0.00$202.61M0.00500 Related Companies and Tools Related Companies Better Therapeutics Competitors UpHealth Competitors OpGen Competitors Aclarion Competitors American Oncology Network Competitors Digital Health Acquisition Competitors LifeMD Competitors Ontrak Competitors P3 Health Partners Competitors Talkspace Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BACK) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IMAC Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IMAC With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access